These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18437725)

  • 1. Torcetrapib and coronary events.
    Dullaart RP; Kobold AC; van Tol A
    N Engl J Med; 2008 Apr; 358(17):1863; author reply 1863-4. PubMed ID: 18437725
    [No Abstract]   [Full Text] [Related]  

  • 2. Torcetrapib and coronary events.
    Lackner KJ
    N Engl J Med; 2008 Apr; 358(17):1862-3; author reply 1863-4. PubMed ID: 18434657
    [No Abstract]   [Full Text] [Related]  

  • 3. Torcetrapib: when global risk reduction goes 'off target'.
    Jackson G
    Int J Clin Pract; 2008 Feb; 62(2):173-4. PubMed ID: 18199271
    [No Abstract]   [Full Text] [Related]  

  • 4. Illuminating HDL--is it still a viable therapeutic target?
    Rader DJ
    N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168
    [No Abstract]   [Full Text] [Related]  

  • 5. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
    Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
    J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
    Kontush A; Guérin M; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torcetrapib and coronary events.
    Cohn LJ
    N Engl J Med; 2008 Apr; 358(17):1863; author reply 1863-4. PubMed ID: 18437724
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of torcetrapib in patients at high risk for coronary events.
    Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
    N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 10. The failure of torcetrapib: was it the molecule or the mechanism?
    Tall AR; Yvan-Charvet L; Wang N
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].
    Rensen PC; Jukema JW
    Ned Tijdschr Geneeskd; 2008 May; 152(19):1088-90. PubMed ID: 18552062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of dalcetrapib.
    Stein EA; Stroes ES; Steiner G; Buckley BM; Capponi AM; Burgess T; Niesor EJ; Kallend D; Kastelein JJ
    Am J Cardiol; 2009 Jul; 104(1):82-91. PubMed ID: 19576325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of torcetrapib, a lipid-lowering drug, abandoned.
    Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590910
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL: back to the drawing board.
    Johns Hopkins Med Lett Health After 50; 2007 May; 19(3):1-2. PubMed ID: 17657883
    [No Abstract]   [Full Text] [Related]  

  • 18. The failure of torcetrapib: what have we learned?
    Joy TR; Hegele RA
    Br J Pharmacol; 2008 Aug; 154(7):1379-81. PubMed ID: 18536741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
    Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein inhibition: a dysfunctional endothelium.
    Westerterp M; Koetsveld J; Tall AR
    J Cardiovasc Pharmacol; 2010 May; 55(5):456-8. PubMed ID: 20351566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.